NCT03962543 2026-04-08ReNeuSpringWorks Therapeutics, Inc.Phase 2 Active not recruiting114 enrolled 25 charts 3 FDA
NCT05028166 2026-03-27Individual Patient Compassionate Use of MirdametinibSpringWorks Therapeutics, Inc.Available